CLDX, US15117B2025

HC Wainwright sets USD 64.00 target for Celldex Therapeutics stock

Published on 10/20/2026 at 19:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 0.02 million while earnings per share were minus USD 0.94. Celldex stock costs EUR 27.00 on October 20, 2026 at 6:48 p.m. CEST.

Analyst target and earnings

HC Wainwright set a USD 64.00 target and a Buy rating on October 2, 2026.
Celldex reported USD 0.02 million in second-quarter revenue and minus USD 0.94 earnings per share.
Celldex stock costs EUR 27.00 at Lang & Schwarz on October 20, 2026 at 6:48 p.m. CEST.
Celldex is scheduled to report earnings on November 9, 2026.

CLDX, US15117B2025, Illustration mit AI erstellt.

HC Wainwright reiterated a Buy rating and set a USD 64.00 price target for Celldex Therapeutics on October 2, 2026, according to MarketBeat. That target is 111.22 percent above the USD 30.30 Nasdaq price on October 20, 2026. Celldex was trading at EUR 27.00 at Lang & Schwarz on October 20, 2026 at 6:48 p.m. CEST.

Second-quarter losses set the backdrop

Celldex reported USD 0.02 million in second-quarter revenue and minus USD 0.94 earnings per share for the period ended June 30, 2026. The earnings-per-share figure was better than the USD 1.06 loss that analysts had expected, while revenue remained below the USD 0.73 million estimate, according to MarketBeat. The contrast leaves the clinical pipeline as the main valuation reference rather than current sales.

Nasdaq range keeps risk visible

On the Nasdaq, Celldex traded at USD 30.30 at 12:58 p.m. ET on October 20, 2026. The same market data put the 52-week range at USD 22.10 to USD 45.14 and market capitalization at USD 2.4 billion. The price therefore sat USD 14.84 below the yearly high and USD 8.20 above the yearly low.

What comes next for valuation?

Celldex's next scheduled earnings date is November 9, 2026, as listed on the company's investor-relations page at Celldex. The date gives investors a defined checkpoint for cash use, clinical progress and any update to the development timetable. Celldex describes its business as focused on antibody-based treatments for inflammatory, allergic, autoimmune and cancer indications.

Peer prices show a mixed session

Regeneron traded at USD 792.65 on October 20, 2026, up 1.36 percent, with a P/E ratio of 19.62 and market capitalization of USD 81.6 billion. Alnylam traded at USD 230.38, down 1.25 percent, with a P/E ratio of 38.90 and market capitalization of USD 30.8 billion. Celldex's USD 2.4 billion valuation is smaller than both peers, while its negative earnings keep a conventional positive P/E comparison unavailable.

Celldex stock remains tied to targets

The USD 64.00 HC Wainwright target is the clearest dated valuation marker in the current coverage. Its 111.22 percent distance from the Nasdaq price also shows how much of the investment case depends on future clinical execution rather than second-quarter revenue.

The further course of trading is shown by the continuously updated real-time quote of Celldex Therapeutics stock.